A New Era of ADC Development

Antibody‑drug conjugates are reshaping oncology and expanding into new therapeutic areas, but advancing modern ADCs requires more than scientific innovation alone. Increasing regulatory expectations, complex dose‑optimization strategies, biomarker‑driven trial designs, and global operational demands are redefining how ADC programs must be executed. This white paper explores why sponsors are partnering with specialized CROs to navigate the scientific, operational and logistical realities of next‑generation ADC development, while accelerating decisions and protecting patient safety.

• How evolving ADC science and design are driving new clinical and operational requirements
• Why dose optimization and regulatory readiness are central to early phase ADC success
• The growing role of AI, predictive analytics and biomarker strategy in ADC trial design
• Considerations for globalizing ADC trials, including APAC and emerging regions
• Practical approaches to managing ADC‑specific operational and supply‑chain complexity

Download the white paper to gain actionable insights from IQVIA Biotech’s deep ADC and oncology development expertise.

Want more? Watch the webinar.